FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvasilington,	D.C.	20040

<b>STATEMENT</b>	OF CHANGES	IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response.	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

O'Maho (Last) C/O LEA	ONY JOHN (F AP THERA RNDIKE S	irst) PEUTICS, INC. FREET, SUITE	(Middle) B1-1		2. Issuer Name and Ticker or Trading Symbol LEAP THERAPEUTICS, INC. [ LPTX ]  3. Date of Earliest Transaction (Month/Day/Year) 01/26/2021  4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Inc	S. Relationship of Reporting Person(s) to Issuer (Check all applicable)     Director						
(City)	(S	tate)	(Zip)		Person														
1. Title of Security (Instr. 3)  2. Transa Date (Month/E				2. Transa Date Month/Da	rative Securities Acquiaction Day/Year)  2A. Deemed Execution Date, if any (Month/Day/Year)  tive Securities Acquiactive Securities Acqui			3. Transact Code (In: 8) Code	ion str.	4. Securi	ties Acquired Of (D) (Ins	ed (A) or tr. 3, 4 and 5	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership Instr. 4)		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	Coc	nsaction le (Instr.	Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and of Securiti Underlying Derivative (Instr. 3 ar	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)			
				Cod	le V	(A) (I		Date Exercisable	Exp Date	oiration e	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)					
Employee Stock Option (Right to Buy)	\$2.57	01/26/2021		A		150,000		(1)	01/2	25/2031	Common Stock	150,000	\$0	150,00	00	D			
Restricted Stock Units	\$0 <sup>(2)</sup>	01/26/2021		A		50,000		(3)		(3)	Common Stock	50,000	\$0 <sup>(2)</sup>	50,000	0	D			

## **Explanation of Responses:**

- 1. The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of January 26, 2021, the Vesting Start Date.
- 2. The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock.
- 3. The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier.

/s/ Douglas E. Onsi, as attorney-01/28/2021 in-fact for John Mark O'Mahony

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.